After a decade of development, a Kansas City-based pharmaceutical company is on the brink of submitting its ADHD medication ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The Trump administration is now accepting applications for a pilot program to demo rebates for 340B drugs that drugmakers ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.

When surgeons repair tissues, they're currently limited to mechanical solutions such as sutures and staples, which can cause their own damage, or meshes and glues that may not adequately bond with ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

The key news from the release was that while the company outperformed revenue estimates—reporting $28.2 million (GAAP) compared to the expected $27.03 million—profitability came under pressure, with a ...

Corcept revised its full-year 2025 revenue guidance to $850-900 million, with the midpoint of $875 million falling below the consensus estimate of $899 million. The company’s stock declined following ...

The court should adopt a narrow view of the Mann Act, the legal team states in a new filing, calling its application in Sean ...

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s executive leadership team will host the call, which ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...